In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascent Pharmahealth Ltd.

Division of Allergan PLC
www.ascentpharmahealth.com.au

Latest From Ascent Pharmahealth Ltd.

Strides Focuses On Emerging Markets After ‘Challenging’ Q1

Indian drug maker Strides Arcolab, rated by local analysts as one of the top small-cap pharma picks, says it is betting on emerging markets, ramping up research and development and scouting for new acquisitions to drive earnings following a “challenging” fiscal first quarter.

BioPharmaceutical Asia Pacific

Strides ‘Ver. 2’ Aims To Pack Punch For Premium Value

Bangalore-based Strides Arcolab is arguably a restless company. Industry and investment bankers know it as a hyperactive deal maker, either buying companies cheap or selling off units at high premiums. Even as the firm is in the process of rebuilding into what it calls Version 2, founder and CEO Arun Kumar is keeping his options open on doing what he is best known for – buying and selling to create shareholder value.

BioPharmaceutical Asia Pacific

Asia Firmly On The Radar For Actavis/Allergan

For a company that took a step back from China at the beginning of this year, Actavis is again keen to stress that its $66 billion acquisition of Allergan will give it a stronger presence in Asia, including in the key markets of China and India.

BioPharmaceutical Asia Pacific

Actavis’ Transformative Dealmaking

A steady stream of M&A and licensing activity, starting with the buyout of Andrx in 2006, spurred Actavis’ a.k.a. Watson’s transformation into a global specialty pharma. This led the way to the 2012 merger with Actavis and now the proposed buyout of Forest, creating a new, global specialty and generics player.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Genepharm Australasia Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Dennis Bastas, CEO
    Andrew Burgess, CFO
    A. Heine, General Manager, Sales & Mktg.
    Stephen L Blank, SVP, Strategy & Dev.
  • Contact Info
  • Ascent Pharmahealth Ltd.
    Phone: (61) 03 8677 6660
    151-153 Claredon St.
    South Melbourne, 3205
    Australia
UsernamePublicRestriction

Register